The PAPZIMEOS launch is accelerating faster than expected, with Q1 revenue already exceeding the prior quarter's full-year total. The permanent J-code taking effect in April should further boost site activations and patient starts in Q2. Watch for continued revenue growth and progress toward cash flow break-even by year-end. The upcoming ASCO presentation (May 29-June 2) may provide additional catalyst on durability data.
PGEN drugs
PGEN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $4.60entry
- T+1 · 6mo ago 0.00%α −0.01% · $4.60
- T+5 · 6mo ago −6.96%α −6.24% · $4.28
- T+20 · 5mo ago −3.26%α −2.40% · $4.45
- T+60 · 3mo ago +52.17%α +48.59% · $7.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product revenue in its first full commercial quarter. Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025, as the company transitions to a commercial-stage biopharma. The strong launch trajectory and cash position of $56.7M support management's expectation of reaching cash flow break-even by end of 2026.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue of $23.3M, up from $1.3M in Q1 2025, driven by $21.6M in PAPZIMEOS net product revenue
- Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025
- Cash, cash equivalents, and investments totaled $56.7M as of March 31, 2026
- Approximately $25.7M in PAPZIMEOS-related accounts receivable not yet collected as of quarter-end
- Company expects current cash plus anticipated PAPZIMEOS revenue to fund operations to cash flow break-even by end of 2026
- Patient hub enrollment surpassed 400 patients, with 25% from community settings
- Permanent J-code (J3404) effective April 1, 2026, expected to further streamline reimbursement and site activations
Financial Impact
Q1 2026 product revenue of $21.6M vs $0.2M in Q1 2025; net loss improved by $46.3M year-over-year
Risk Factors
- Dependence on single product PAPZIMEOS for revenue; any commercial disruption would be material
- Cash burn remains significant; break-even timeline depends on continued revenue acceleration
- Long-term debt of $93.5M adds financial leverage and interest expense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-007158 |
| Document: dp246650_8k.htm | 0000950103-26-007158 |
| Document: 0000950103-26-007158-index-headers.html | 0000950103-26-007158 |
| Document: 0000950103-26-007158-index.html | 0000950103-26-007158 |
| Document: 0000950103-26-007158.txt | 0000950103-26-007158 |
| 8-K Data (Synthetic) | 0000950103-26-007158 |
Track record
13 reports on PGEN
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.43% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers